<DOC>
	<DOCNO>NCT00000961</DOCNO>
	<brief_summary>To determine safety tolerance hyperimmune anti-HIV intravenous immunoglobulin ( HIVIG ) zidovudine ( AZT ) infant establish HIV infection ; get preliminary evidence effectiveness type treatment prevent advance disease HIV infect infant . HIVIG may effective agent either alone combination AZT prevent progression clinical disease .</brief_summary>
	<brief_title>The Safety Effectiveness Hyperimmune Anti-HIV Intravenous Immunoglobulin ( HVIG ) Plus Zidovudine HIV-Infected Infants</brief_title>
	<detailed_description>HIVIG may effective agent either alone combination AZT prevent progression clinical disease . Participants randomize receive either oral AZT HIVIG . Patients may receive treatment maximum 48 week . Patients evaluate treatment week 2 , 4 , every 4 week thereafter . Infants receive HIVIG initially treat appropriate age-adjusted dose oral AZT addition HIVIG meet clinical disease progression criterion . All participant complete 48 week treatment discontinue treatment follow every 3 month additional 48 week . This follow-up may conduct telephone .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immune Sera</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Recommended : Standard immunization . Should repeat MMR 3 month discontinue study . Benadryl and/or aspirin . Pneumocystis carinii pneumonia prophylaxis . Systemic ketoconazole acyclovir , oral nystatin acute therapy . Aerosol ribavirin shortterm treatment RSV . Concurrent Treatment : Allowed : Blood transfusion . Patients must follow : Parent guardian available give write informed consent . Protocol require prior Institutional Review Board ( IRB ) approval subject enter study . Prior Medication : Allowed : Gammaglobulin , intravenous ( IV ) intramuscular ( IM ) . Immunoglobulin , IV ( IVIG ) . Maternal antiretroviral treatment pregnancy . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Symptomatic class P2 symptom ( except lymphadenopathy time study entry . Presence serious acute infection require parenteral treatment time study entry . Concurrent Medication : Excluded : Prophylaxis oral candidiasis otitis medium infection . Immunoglobulin therapy ( except single dose hypogammaglobulinemia ) . Ketoconazole , acyclovir , nystatin prophylaxis . Patients follow exclude : Symptomatic class P2 symptom ( except lymphadenopathy time study entry . Presence serious acute infection require parenteral treatment time study entry . Prior Medication : Excluded : Antiretroviral treatment experimental treatment within 2 week entry .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>March 1998</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
</DOC>